Document Detail

Effects of 2-chloro-2'-deoxyadenosine on the cell cycle in the human leukemia EHEB cell line.
MedLine Citation:
PMID:  15571271     Owner:  NLM     Status:  MEDLINE    
To explain why 2-chloro-2'-deoxyadenosine (CdA) is unable to block DNA synthesis and cell cycle progression, and paradoxically enhances progression from G1 into S phase in the CdA-resistant leukemia EHEB cell line, we studied its metabolism and effects on proteins regulating the transition from G1 to S phase. A low deoxycytidine kinase activity and CdATP accumulation, and a lack of p21 induction despite p53 phosphorylation and accumulation may account for the inability of CdA to block the cell cycle. An alternative pathway involving pRb phosphorylation seems implicated in the CdA-induced increase in G1 to S phase progression.
S Cardoen; E Van den Neste; C Smal; J F Rosier; A Ferrant; G Van den Berghe; F Bontemps
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nucleosides, nucleotides & nucleic acids     Volume:  23     ISSN:  1525-7770     ISO Abbreviation:  Nucleosides Nucleotides Nucleic Acids     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-12-01     Completed Date:  2005-02-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100892832     Medline TA:  Nucleosides Nucleotides Nucleic Acids     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1425-9     Citation Subset:  IM    
Laboratory of Physiological Chemistry, Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / pharmacology
Antineoplastic Agents / pharmacology
Blotting, Western
Bromodeoxyuridine / pharmacology
Cell Cycle
Cell Cycle Proteins / metabolism
Cell Line, Tumor
Chromatography, High Pressure Liquid
Cladribine / pharmacology*
Cyclin-Dependent Kinase Inhibitor p21
DNA / biosynthesis,  metabolism
Deoxycytidine Kinase / metabolism
Dose-Response Relationship, Drug
Enzyme Inhibitors / metabolism
Flow Cytometry
G1 Phase
Inhibitory Concentration 50
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*,  metabolism
Models, Biological
S Phase
Time Factors
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 0/CDKN1A protein, human; 0/Cell Cycle Proteins; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Enzyme Inhibitors; 4291-63-8/Cladribine; 59-14-3/Bromodeoxyuridine; 9007-49-2/DNA; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Next Document:  Management of hyperuricemia with rasburicase review.